Archive

Ending Rheumatic Heart Disease is achievable if we put our heads and minds to it
Ending Rheumatic Heart Disease is achievable if we put our heads and minds to it Preventable, yet persistent, Rheumatic Heart Disease (RHD) is the most commonly acquired heart disease in people under 25 years of age. The World Heart Federation (WHF) is committed to the fight to ensure cardiovascular health for everyone. Through WHF’s network of Members and the power of personal testimonials, we are spreading awareness that RHD can be prevented, diagnosed, and treated. This editorial was authored by WHF Director of Policy and Advocacy Jeremiah Mwangi and was first published in FORESIGHT Global Health on 19 August 2021.


Dear colleagues!
Dear colleagues! I welcome you on behalf of the Organizing Committee of the XI International Forum for Cardiology and Internal Medicine, which will be held from March 22 to 24, 2022 in Moscow.


Polypill Shows LDL-Lowering Advantage in High-risk Primary Prevention Patients: VULCANO
Polypill Shows LDL-Lowering Advantage in High-risk Primary Prevention Patients: VULCANO Key Takeaways The CNIC (Centro Nacional de Investigaciones Cardiovasculares) polypill contains acetylsalicylic acid (100 mg), atorvastatin (30 mg or 40 mg), and ramipril (2.5 mg, 5 mg, or 10 mg), and is the only polypill for cardiovascular disease (CVD) currently marketed in European countries.


Heart Disease and Stroke Statistics—2022 Update: A Report From the American Heart Association
Heart Disease and Stroke Statistics—2022 Update: A Report From the American Heart Association The American Heart Association, in conjunction with the National Institutes of Health, annually reports the most up-to-date statistics related to heart disease, stroke, and cardiovascular risk factors, including core health behaviors (smoking, physical activity, diet, and weight) and health factors (cholesterol, blood pressure, and glucose control) that contribute to cardiovascular health.


The Scientific Committee begins accepting abstracts and applications for the scientific program of the XI International Forum of Cardiology and Internal Medicine
The Scientific Committee begins accepting abstracts and applications for the scientific program of the XI International Forum of Cardiology and Internal Medicine Dear Colleagues! We invite you to take part in XI International Forum of Cardiology and Internal Medicine. Forum will take place on 22-24 March 2022 in Moscow (online).


Analysis of the activities of the
Analysis of the activities of the "Cardioprogress" foundation: results of 2021 Dear colleagues! In 2021, a number of significant events took place in cardiology. Due to the continuation of restrictive measures, most scientific events were organized online. This required adaptation and the acquisition of new skills. However, all planned events took place.


Aspirin is linked with increased risk of heart failure
Aspirin is linked with increased risk of heart failure Aspirin use is associated with a 26% raised risk of heart failure in people with at least one predisposing factor for the condition. That’s the finding of a study published today in ESC Heart Failure, a journal of the European Society of Cardiology (ESC).


Depression worsened during pandemic, boosting heart disease risk, experts warn
Depression worsened during pandemic, boosting heart disease risk, experts warn It may translate into another long-term effect of the coronavirus crisis — more heart disease cases even in people who never had COVID-19 at all. More than one-third of patients studied reported becoming depressed or experiencing continued symptoms of depression during the first year of the pandemic.


Longer Sleep Improves Cardiovascular Outcomes: Time to Make Sleep a Priority
Longer Sleep Improves Cardiovascular Outcomes: Time to Make Sleep a Priority Causal diagrams demonstrating potential relationships between genetic causes (G) of sleep duration, sleep duration (S), and a cardiovascular outcome (Y). (A) G is a valid instrumental variable for the relationship of S and Y, and can be used to estimated the S–Y association (orange arrow). (B) G has a pleiotropic association with Y. Because there are no unmeasured confounders (U) of the S–Y association, causal mediation analysis can be used to estimate both the direct (pleiotropic) association of G and Y, and the indirect effect via S. (C) The pleiotropic effect of G on Y can be measured by blocking the pathway through S, which is done by conditioning on levels of S. (D) The effect of S on Y independently of G can be measured by blocking pathways through G and C (measured confounders) by conditioning or using matching methods.


Medscape and ACC Centers of Excellence
Medscape and ACC Centers of Excellence The ACC has collaborated with Medscape to create two Centers of Excellence on the topics of Cardiovascular Risk Reduction and Heart Failure.